Inoxgen (Nitric Oxide)

Nitric oxide released in the lungs diffuses into vascular smooth‑muscle cells, activates soluble guanylate cyclase, raises cGMP, causing relaxation of pulmonary arterial smooth muscle and selective vasodilation of ventilated lung regions, thereby lowering pulmonary artery pressure.

The dose of Inoxgen is individualized by the prescribing clinician based on the patient’s age, weight, severity of pulmonary hypertension, and response to therapy; dosing regimens are established in the product’s prescribing information and should not be altered without medical supervision.

Safety data for inhaled nitric oxide in pregnant or lactating women are limited; the product should be used only if the potential benefit justifies the potential risk, and the decision must be made by the treating physician.

To request Inoxgen, submit an enquiry on the product page at gnhindia.com specifying the required quantity. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details (including any cold‑chain requirements) and necessary import documentation.

Inoxgen delivers nitric oxide directly to the lungs, providing rapid, selective pulmonary vasodilation with minimal systemic effects, whereas oral agents such as phosphodiesterase‑5 inhibitors act systemically and have a slower onset. Compared with inhaled prostacyclin analogues, nitric oxide has a shorter half‑life and can be titrated more precisely.

Inoxgen cylinders should be stored at ambient temperature, kept upright, protected from heat, direct sunlight and physical damage. The cylinders must be secured to prevent tipping and handled only by trained personnel following local safety regulations.

Inoxgen is supplied as a medical gas in calibrated cylinders and is administered via an endotracheopulmonary inhalation system. The gas is mixed with carrier oxygen and delivered through a ventilator or breathing circuit, allowing precise control of the inhaled concentration under continuous monitoring.

The most serious adverse events include the development of methemoglobinemia, severe systemic hypotension, and rebound pulmonary hypertension after abrupt discontinuation. These risks require regular monitoring of blood pressure, methemoglobin levels, and careful weaning of therapy.

Inoxgen is contraindicated in patients with known hypersensitivity to nitric oxide, those with severe methemoglobinemia, or individuals in whom rapid reduction of pulmonary pressure could precipitate hemodynamic instability. Use should also be avoided in patients receiving certain interacting medications without appropriate monitoring.